[{"id":"b44521d2-5829-4bf3-b6c2-ad08cfcaf642","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863805","created_at":"2025-07-19T14:06:15.287Z","updated_at":"2025-07-19T14:06:15.287Z","phase":"","brief_title":"Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","source_id_and_acronym":"NCT06863805","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" BRAF • ALK • RET • RAS • NTRK","pipe":" | ","alterations":" RAS mutation • RET mutation","tags":["BRAF • ALK • RET • RAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-03-07"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"1c396f9f-301a-4705-afde-65c99cd26512","acronym":"LIBRETTO-321","url":"https://clinicaltrials.gov/study/NCT04280081","created_at":"2021-01-18T20:46:57.085Z","updated_at":"2025-02-25T16:32:06.121Z","phase":"Phase 2","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","source_id_and_acronym":"NCT04280081 - LIBRETTO-321","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-07"},{"id":"a58385e3-f746-48dd-bf8f-10d8e83d28bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01708954","created_at":"2021-01-18T07:26:37.698Z","updated_at":"2025-02-25T16:36:12.668Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01708954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • RET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion","tags":["HER-2 • KRAS • BRAF • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 08/14/2015","primary_completion_date":" 08/14/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"05512785-f9fe-439d-9e0c-f165bade4b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206060","created_at":"2021-01-18T15:48:09.116Z","updated_at":"2025-02-25T16:44:08.576Z","phase":"Phase 2","brief_title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","source_id_and_acronym":"NCT03206060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • VHL • SSTR","pipe":" | ","alterations":" RET mutation • VHL mutation","tags":["NF1 • VHL • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-05"},{"id":"fc12ec5e-bd90-482d-9d25-a68cd6f10bca","acronym":"LIBRETTO-531","url":"https://clinicaltrials.gov/study/NCT04211337","created_at":"2021-01-18T20:30:33.890Z","updated_at":"2025-02-25T16:52:48.085Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","source_id_and_acronym":"NCT04211337 - LIBRETTO-531","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"402908a9-d0e1-4f21-92f5-1af6168ee4aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06141005","created_at":"2025-02-26T07:39:11.997Z","updated_at":"2025-02-26T07:39:11.997Z","phase":"","brief_title":"Feasibility of Bronchial Washing Fluid for Molecular Testing with Next Generation Sequencing in Lung Cancer","source_id_and_acronym":"NCT06141005","lead_sponsor":"Pusan National University Hospital","biomarkers":" EGFR • HER-2 • ALK • RET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • RET mutation • ROS1 fusion","tags":["EGFR • HER-2 • ALK • RET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • RET mutation • ROS1 fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/29/2024","primary_completion_date":" 08/29/2024","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-01-03"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"fe141ae7-4238-43b1-a6a8-019252bc4d9e","acronym":"KEYNOTE F92","url":"https://clinicaltrials.gov/study/NCT05597839","created_at":"2022-10-28T13:56:59.300Z","updated_at":"2025-02-25T16:18:16.558Z","phase":"Phase 1/2","brief_title":"Study of DF9001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05597839 - KEYNOTE F92","lead_sponsor":"Dragonfly Therapeutics","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" RET mutation • RAS wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • DF9001"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-05-15"},{"id":"1cb5fcda-fc0d-47da-bc21-1ef95536ae56","acronym":"STAR-121","url":"https://clinicaltrials.gov/study/NCT05502237","created_at":"2022-08-16T11:56:10.218Z","updated_at":"2024-07-02T16:35:06.556Z","phase":"Phase 3","brief_title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05502237 - STAR-121","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK mutation • RET mutation","tags":["EGFR • BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-05-01"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"6599101d-aea2-4fda-beb6-038d37252237","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440735","created_at":"2023-04-26T18:04:49.712Z","updated_at":"2024-07-02T16:35:11.822Z","phase":"Phase 1/2","brief_title":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04440735","lead_sponsor":"Kahr Medical","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DSP-107"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"},{"id":"a9ff4f76-2282-4d1f-9d45-07b786992ee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241834","created_at":"2022-02-16T18:53:36.129Z","updated_at":"2024-07-02T16:35:12.547Z","phase":"Phase 1","brief_title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","source_id_and_acronym":"NCT05241834","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-27"},{"id":"1cd4bf5f-edfe-4d2a-b079-73a5000d620a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225259","created_at":"2022-02-05T18:29:52.250Z","updated_at":"2024-07-02T16:35:17.299Z","phase":"","brief_title":"Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor","source_id_and_acronym":"NCT05225259","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LOXO-260"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-28"},{"id":"c459c21e-279b-40e7-a0c3-b69256f31293","acronym":"","url":"https://clinicaltrials.gov/study/NCT04143711","created_at":"2021-01-18T20:13:28.416Z","updated_at":"2024-07-02T16:35:21.935Z","phase":"Phase 1/2","brief_title":"Study of DF1001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04143711","lead_sponsor":"Dragonfly Therapeutics","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • DF1001"],"overall_status":"Recruiting","enrollment":" Enrollment 378","initiation":"Initiation: 11/11/2019","start_date":" 11/11/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-29"},{"id":"557b19f9-7188-4df8-9db3-bfc502e77692","acronym":"AcceleRET-MTC","url":"https://clinicaltrials.gov/study/NCT04760288","created_at":"2021-02-18T22:55:15.019Z","updated_at":"2024-07-02T16:35:24.361Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","source_id_and_acronym":"NCT04760288 - AcceleRET-MTC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET • CEACAM5","pipe":" | ","alterations":" RET mutation","tags":["RET • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Gavreto (pralsetinib) • Caprelsa (vandetanib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 04/12/2035","study_completion_date":" 04/12/2035","last_update_posted":"2024-01-05"},{"id":"cc6784ad-5408-45ec-a940-e7803eaea6ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777175","created_at":"2021-03-02T12:52:17.480Z","updated_at":"2024-07-02T16:35:25.196Z","phase":"","brief_title":"A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04777175","lead_sponsor":"Yongchang Zhang","biomarkers":" HER-2 • BRAF • ALK","pipe":" | ","alterations":" BRAF mutation • HER-2 mutation • ALK mutation • RET mutation • MET mutation","tags":["HER-2 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 mutation • ALK mutation • RET mutation • MET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/12/2025","study_completion_date":" 01/12/2025","last_update_posted":"2023-12-27"},{"id":"92317f6b-e36a-4f47-bb43-ac7bcf194fe8","acronym":"INOND","url":"https://clinicaltrials.gov/study/NCT06180005","created_at":"2023-12-22T16:17:46.866Z","updated_at":"2024-07-02T16:35:25.462Z","phase":"","brief_title":"Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)","source_id_and_acronym":"NCT06180005 - INOND","lead_sponsor":"Centro di Riferimento Oncologico - Aviano","biomarkers":" EGFR • HER-2 • BRAF • ALK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • RET mutation","tags":["EGFR • HER-2 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • RET mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 01/02/2024","start_date":" 01/02/2024","primary_txt":" Primary completion: 01/02/2039","primary_completion_date":" 01/02/2039","study_txt":" Completion: 12/30/2039","study_completion_date":" 12/30/2039","last_update_posted":"2023-12-22"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"},{"id":"a54c5bf1-77a7-4e44-bb57-e245104dfd72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780517","created_at":"2021-01-18T18:41:54.388Z","updated_at":"2024-07-02T16:35:31.196Z","phase":"Phase 1","brief_title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","source_id_and_acronym":"NCT03780517","lead_sponsor":"Boston Pharmaceuticals","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeteletinib (BOS-172738)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2023-10-30"},{"id":"3a82e04d-c9f4-47e8-a785-460ee3d906aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900935","created_at":"2021-05-25T18:52:41.072Z","updated_at":"2024-07-02T16:35:32.075Z","phase":"","brief_title":"Patient-centered, Optimal Integration of Survivorship and Palliative Care","source_id_and_acronym":"NCT04900935","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • RET mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-10-23"}]